Your browser is no longer supported. Please, upgrade your browser.
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own0.20% Shs Outstand45.45M Perf Week10.09%
Market Cap1.95B Forward P/E- EPS next Y-1.75 Insider Trans-22.55% Shs Float44.16M Perf Month-12.57%
Income-72.30M PEG- EPS next Q-0.47 Inst Own94.20% Short Float8.20% Perf Quarter-26.10%
Sales8.10M P/S241.27 EPS this Y42.50% Inst Trans19.99% Short Ratio8.51 Perf Half Y30.01%
Book/sh9.61 P/B4.13 EPS next Y-11.90% ROA-25.80% Target Price65.17 Perf Year117.10%
Cash/sh8.60 P/C4.62 EPS next 5Y- ROE-28.30% 52W Range15.37 - 57.20 Perf YTD126.77%
Dividend- P/FCF- EPS past 5Y36.60% ROI-29.70% 52W High-30.54% Beta2.76
Dividend %- Quick Ratio30.10 Sales past 5Y6.20% Gross Margin- 52W Low158.49% ATR2.52
Employees123 Current Ratio30.10 Sales Q/Q-71.40% Oper. Margin- RSI (14)44.70 Volatility6.70% 6.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-24.30% Profit Margin- Rel Volume0.67 Prev Close38.77
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume425.73K Price39.73
Recom1.70 SMA20-3.06% SMA50-13.10% SMA2005.68% Volume283,133 Change2.48%
Sep-17-21Initiated Jefferies Buy $66
Sep-10-21Initiated SVB Leerink Outperform $68
Jul-22-21Initiated Guggenheim Buy $66
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Dec-08-21 08:01AM  
Nov-12-21 07:00AM  
Nov-11-21 07:01AM  
Nov-09-21 06:15PM  
Oct-28-21 03:05PM  
Oct-25-21 11:51AM  
Sep-29-21 08:13AM  
Sep-24-21 07:01AM  
Sep-23-21 08:01AM  
Sep-16-21 07:01AM  
Sep-14-21 10:31AM  
Sep-13-21 09:01AM  
Aug-25-21 03:55PM  
Aug-05-21 06:05PM  
Jul-29-21 03:05PM  
Jul-24-21 07:04AM  
Jul-18-21 03:39AM  
Jul-16-21 04:01PM  
Jul-14-21 03:21PM  
Jul-13-21 08:30PM  
Jul-12-21 04:27PM  
Jul-09-21 06:01PM  
Jun-04-21 09:01AM  
Jun-01-21 07:31AM  
May-26-21 04:01PM  
May-13-21 03:18AM  
May-06-21 06:35PM  
Apr-20-21 11:56AM  
Apr-12-21 04:01PM  
Apr-10-21 06:13AM  
Apr-06-21 09:05AM  
Mar-29-21 04:01PM  
Mar-05-21 01:00PM  
Feb-23-21 06:01AM  
Feb-22-21 04:01PM  
Jan-26-21 12:39AM  
Jan-08-21 08:51AM  
Jan-04-21 08:01AM  
Dec-23-20 06:55AM  
Dec-09-20 08:01AM  
Nov-30-20 04:01PM  
Nov-27-20 12:30AM  
Nov-09-20 08:01AM  
Nov-05-20 05:55PM  
Nov-03-20 12:31PM  
Oct-15-20 08:14PM  
Oct-14-20 11:32AM  
Oct-13-20 08:01AM  
Oct-06-20 06:09PM  
Sep-29-20 08:58AM  
Sep-10-20 04:01PM  
Aug-25-20 01:25PM  
Aug-24-20 08:01AM  
Aug-06-20 04:01PM  
Aug-03-20 08:01AM  
Jul-29-20 12:33PM  
Jul-09-20 11:01AM  
Jul-08-20 07:32AM  
Jun-18-20 10:31AM  
Jun-15-20 10:35PM  
Jun-12-20 10:39AM  
Jun-11-20 10:39AM  
Jun-09-20 07:46AM  
Jun-06-20 03:01AM  
May-28-20 03:22PM  
May-25-20 11:30AM  
May-06-20 04:01PM  
Apr-24-20 08:56AM  
Apr-14-20 08:37AM  
Apr-06-20 08:53AM  
Mar-26-20 04:01PM  
Mar-03-20 08:01AM  
Dec-23-19 10:26AM  
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin Samuel BatesSVP and CFONov 15Option Exercise5.687,00039,72936,378Nov 17 04:02 PM
Martin Samuel BatesSVP and CFONov 15Sale43.579,500413,88326,878Nov 17 04:02 PM
Young Diane C.SVP, Chief Medical OfficerNov 12Option Exercise10.384,60047,7486,715Nov 16 04:02 PM
Young Diane C.SVP, Chief Medical OfficerNov 12Sale42.944,600197,5292,115Nov 16 04:02 PM
Crowley ElizabethSr. VP &CPDONov 01Option Exercise2.788,55523,7839,043Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsNov 01Option Exercise2.786001,66811,847Nov 03 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Nov 01Option Exercise8.035,95647,8527,731Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsNov 01Sale41.7160025,02611,247Nov 03 04:02 PM
Crowley ElizabethSr. VP &CPDONov 01Sale43.294,317186,8744,726Nov 03 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Nov 01Sale43.267,323316,804408Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsAug 11Option Exercise9.0210,00090,16511,247Aug 13 06:59 AM
Jimenez Freddy A.SVP & General CounselAug 11Buy46.2843019,900430Aug 13 06:58 AM
Martin Samuel BatesSVP and CFOAug 10Option Exercise5.7821,381123,68830,060Aug 12 10:00 AM
Martin Samuel BatesSVP and CFOAug 10Sale45.252,738123,89418,981Aug 12 10:00 AM
Marucci Anthony SPresident & CEOAug 05Option Exercise42.003,537148,55427,231Aug 09 07:21 AM
Wright Richard M.Sr. VP & CCODec 14Option Exercise6.2120,832129,36511,665Dec 16 04:30 PM
Wright Richard M.Sr. VP & CCODec 14Sale18.6120,832387,611208Dec 16 04:30 PM